Sands, B. E. Et Al. 2019. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. NEW ENGLAND JOURNAL OF MEDICINE , vol.381, no.13 , 1215-1226.

Sands, B. E., Peyrin-Biroulet, L., Loftus, E. V., Danese, S., Colombel, J., TÖRÜNER, M., ... Jonaitis, L.(2019). Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. NEW ENGLAND JOURNAL OF MEDICINE , vol.381, no.13, 1215-1226.

Sands, Bruce Et Al. "Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis," NEW ENGLAND JOURNAL OF MEDICINE , vol.381, no.13, 1215-1226, 2019

Sands, Bruce E. Et Al. "Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis." NEW ENGLAND JOURNAL OF MEDICINE , vol.381, no.13, pp.1215-1226, 2019

Sands, B. E. Et Al. (2019) . "Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis." NEW ENGLAND JOURNAL OF MEDICINE , vol.381, no.13, pp.1215-1226.

@article{article, author={Bruce E. Sands Et Al. }, title={Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis}, journal={NEW ENGLAND JOURNAL OF MEDICINE}, year=2019, pages={1215-1226} }